Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group
- 1 July 2006
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Biopharmaceutical Statistics
- Vol. 16 (3), 275-283
- https://doi.org/10.1080/10543400600614742
Abstract
A PhRMA Working Group on adaptive clinical trial designs has been formed to investigate and facilitate opportunities for wider acceptance and usage of adaptive designs and related methodologies. A White Paper summarizing the findings of the group is in preparation; this article is an Executive Summary for that full White Paper, and summarizes the findings and recommendations of the group. Logistic, operational, procedural, and statistical challenges associated with adaptive designs are addressed. Three particular areas where it is felt that adaptive designs can be utilized beneficially are discussed: dose finding, seamless Phase II/III trials designs, and sample size reestimation.Keywords
This publication has 16 references indexed in Scilit:
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Bayesian Statistics and the Efficiency and Ethics of Clinical TrialsStatistical Science, 2004
- Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN)Stroke, 2003
- On the inefficiency of the adaptive design for monitoring clinical trialsBiometrika, 2003
- Improved Repeated Confidence Bounds in Trials with a Maximal GoalBiometrical Journal, 2003
- Mid‐course sample size modification in clinical trials based on the observed treatment effectStatistics in Medicine, 2003
- A Unified Theory of Two-Stage Adaptive DesignsJournal of the American Statistical Association, 2002
- Competing designs for phase I clinical trials: a reviewStatistics in Medicine, 2002
- Recursive Combination TestsJournal of the American Statistical Association, 2002
- Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteersBiostatistics, 2001